Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Abeona Therapeutics's Days Inventory for the
three
months ended in Mar. 2026 was 194.24.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Abeona Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.66.
Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Abeona Therapeutics's Days Inventory for the
three
months ended in Mar. 2026 is calculated as:
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Abeona Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.
Abeona Therapeutics Inventory Turnover Related Terms
Abeona Therapeutics Inventory Turnover Historical Data
* Premium members only.
The historical data trend for Abeona Therapeutics's Inventory Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abeona Therapeutics (STU:PCJ) has a Inventory Turnover of 0.47 as of Mar. 2026. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Abeona Therapeutics and its competitors.
Is Abeona Therapeutics' Inventory Turnover too high?
Abeona Therapeutics' current Inventory Turnover is 0.47. Overall, Abeona Therapeutics has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Abeona Therapeutics' Inventory Turnover compare to RCKT and UPB?
Abeona Therapeutics' Inventory Turnover of 0.47 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventory Turnover for a Biotechnology company?
A good Inventory Turnover depends on the Biotechnology industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventory Turnover mean?
A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Abeona Therapeutics and its competitors. Abeona Therapeutics's current Inventory Turnover is 0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abeona Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Abeona Therapeutics (STU:PCJ) is currently considered Possible Value Trap. The stock's GF Value™ is €15.12, compared to a current price of €6.23 — trading 58.8% below its estimated fair value. The current Inventory Turnover is 0.47. Abeona Therapeutics' overall GF Score™ is 51/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventory Turnover calculated?
Inventory Turnover is calculated from a company's financial statements. For Abeona Therapeutics (STU:PCJ), the current Inventory Turnover is 0.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abeona Therapeutics (STU:PCJ) Overvalued in 2026?
Based on GuruFocus' analysis, Abeona Therapeutics stock appears to be undervalued.
The current stock price of €6.23 is trading 58.8% below its estimated GF Value™ of €15.12.
GuruFocus considers Abeona Therapeutics to be Possible Value Trap.
Key valuation signals for STU:PCJ:
Inventory Turnover: 0.47
GF Value™: €15.12 vs. price of €6.23 (58.8% below fair value)
No single metric tells the full story. See the STU:PCJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
51GF Score
Get the complete analysis for STU:PCJ
Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:PCJ has been successfully added to your 
